These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 26459901

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R.
    Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
    [Abstract] [Full Text] [Related]

  • 3. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
    Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH.
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and serum concentrations of antimycobacterial drugs in adult Turkish patients.
    Babalık A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildiz L, Çarpaner E.
    Int J Tuberc Lung Dis; 2013 Nov; 17(11):1442-7. PubMed ID: 24125448
    [Abstract] [Full Text] [Related]

  • 5. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
    Fahimi F, Tabarsi P, Kobarfard F, Bozorg BD, Goodarzi A, Dastan F, Shahsavari N, Emami S, Habibi M, Salamzadeh J.
    Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
    [Abstract] [Full Text] [Related]

  • 6. Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients.
    Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE.
    Chest; 1998 May; 113(5):1178-83. PubMed ID: 9596291
    [Abstract] [Full Text] [Related]

  • 7. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
    Babalik A, Ulus IH, Bakirci N, Kuyucu T, Arpag H, Dagyildizi L, Capaner E.
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
    [Abstract] [Full Text] [Related]

  • 8. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK, Günther G, Kibuule D, Hunter C, Rennie TW.
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [Abstract] [Full Text] [Related]

  • 9. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
    Bekker A, Schaaf HS, Draper HR, van der Laan L, Murray S, Wiesner L, Donald PR, McIlleron HM, Hesseling AC.
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
    [Abstract] [Full Text] [Related]

  • 10. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA.
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [Abstract] [Full Text] [Related]

  • 11. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I, Park JS, Cho YJ, Yoon HI, Song J, Lee CT, Lee JH.
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [Abstract] [Full Text] [Related]

  • 12. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK, Chandrasekaran V, Kannan T, Murali AL, Lavanya J, Sudha V, Swaminathan S, Ramachandran G.
    Eur J Clin Pharmacol; 2017 Jan; 73(1):65-70. PubMed ID: 27651240
    [Abstract] [Full Text] [Related]

  • 13. Investigation of Elimination Rate, Persistent Subpopulation Removal, and Relapse Rates of Mycobacterium tuberculosis by Using Combinations of First-Line Drugs in a Modified Cornell Mouse Model.
    Hu Y, Pertinez H, Ortega-Muro F, Alameda-Martin L, Liu Y, Schipani A, Davies G, Coates A.
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4778-85. PubMed ID: 27216065
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
    Tostmann A, Mtabho CM, Semvua HH, van den Boogaard J, Kibiki GS, Boeree MJ, Aarnoutse RE.
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
    Xu J, Jin H, Zhu H, Zheng M, Wang B, Liu C, Chen M, Zhou L, Zhao W, Fu L, Lu Y.
    Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
    [Abstract] [Full Text] [Related]

  • 20. Outcomes of pulmonary tuberculosis in patients with discordant phenotypic isoniazid resistance testing.
    Kim S, Lee H, Park HY, Jeon K, Huh HJ, Lee NY, Jeong BH.
    Respir Med; 2017 Dec; 133():6-11. PubMed ID: 29173450
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.